AMA approves CPT code for Axxent electronic brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

AMA approves CPT code for Axxent electronic brachytherapy

FREMONT, California—Xoft, Inc., maker of the FDA-approved Axxent Electronic Brachytherapy System (see Oncology NEWS International, June 2007, page 34) has announced that Axxent treatment now has a CPT reimbursement code. The American Medical Association CPT Editorial Panel approved the code (Category III CPT Code 0182T) for this novel form of high-dose-rate radiation therapy for the treatment of early-stage breast cancer. The code has been assigned a New Technology Ambulatory Payment Classification (APC), which secures payment for Medicare recipients who receive the treatment in the hospital outpatient setting.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content